全文获取类型
收费全文 | 1010篇 |
免费 | 48篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 34篇 |
妇产科学 | 19篇 |
基础医学 | 140篇 |
口腔科学 | 10篇 |
临床医学 | 79篇 |
内科学 | 274篇 |
皮肤病学 | 24篇 |
神经病学 | 97篇 |
特种医学 | 22篇 |
外科学 | 70篇 |
综合类 | 4篇 |
预防医学 | 76篇 |
眼科学 | 10篇 |
药学 | 54篇 |
中国医学 | 1篇 |
肿瘤学 | 145篇 |
出版年
2024年 | 1篇 |
2023年 | 13篇 |
2022年 | 16篇 |
2021年 | 41篇 |
2020年 | 15篇 |
2019年 | 30篇 |
2018年 | 35篇 |
2017年 | 22篇 |
2016年 | 31篇 |
2015年 | 29篇 |
2014年 | 31篇 |
2013年 | 48篇 |
2012年 | 84篇 |
2011年 | 77篇 |
2010年 | 45篇 |
2009年 | 35篇 |
2008年 | 56篇 |
2007年 | 71篇 |
2006年 | 70篇 |
2005年 | 67篇 |
2004年 | 69篇 |
2003年 | 57篇 |
2002年 | 48篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 9篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 6篇 |
1993年 | 1篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1989年 | 5篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1978年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有1064条查询结果,搜索用时 609 毫秒
21.
Carla Sappino Ludovica Primitivo Martina De Angelis Francesco Righi Federica Di Pietro Marika Iannoni Luciano Pilloni Stefano Vecchio Ciprioti Lorenza Suber Alessandra Ricelli Giuliana Righi 《RSC advances》2020,10(50):29688
A linear β-amino alcohol ligand, previously found to be a very efficient catalyst for enantioselective addition of dialkylzinc to aromatic aldehydes, has been anchored on differently functionalized superparamagnetic core–shell magnetite–silica nanoparticles (1a and 1b). Its catalytic activity in the addition of dialkylzinc to aldehydes has been evaluated, leading to promising results, especially in the case of 1b for which the recovery by simple magnetic decantation and reuse was successfully verified.The catalytic activity of a linear β-amino alcohol ligand anchored on functionalized magnetite/silica core–shell nanoparticles has been evaluated in the addition of dialkylzinc to aldehydes leading to promising results. 相似文献
22.
23.
Tanda ML Piantanida E Lai A Liparulo L Sassi L Bogazzi F Wiersinga WM Braverman LE Martino E Bartalena L 《Clinical endocrinology》2008,69(5):812-818
Objective To investigate how North American thyroidologists assess and treat amiodarone‐induced thyrotoxicosis (AIT) and to compare the results with those of the same questionnaire‐based survey previously carried out among European thyroidologists. Design Members of the American Thyroid Association (ATA) with clinical interests were sent by e‐mail a questionnaire on the diagnosis and management of AIT, 115 responses were received from the United States and Canada, representing about one‐third of ATA members with clinical interests. Results The majority of respondents (91%vs. 68% in Europe, P < 0·05) see < 10 new cases of AIT per year, and AIT seems less frequent than amiodarone‐induced hypothyroidism (AIH) in North America (34% and 66% of amiodarone‐induced thyroid dysfunction, respectively, vs. 75% and 25%, respectively, in Europe, P < 0·001). When AIT is suspected, in North America hormonal assessment is mostly based on serum free T4 (FT4) and TSH measurements, while serum free T3 (FT3) determination is requested less frequently than in Europe; thyroid autoimmunity is included in the initial assessment less than in Europe. Most commonly used additional diagnostic procedures include, as in Europe, thyroid colour‐flow Doppler sonography, and to a lesser extent, thyroid radioactive iodine uptake and scan, but Europeans tend to request multiple tests more than North Americans. Withdrawal of amiodarone is more often considered unnecessary by North American thyroidologists (21%vs. 10% in Europe in type 1 AIT, P < 0·05, 34%vs. 20% in type 2 AIT, P < 0·05). In type 1 AIT thionamides represent the treatment of choice for North Americans as well as for Europeans, but the former use them as monotherapy in 65%vs. 51% of Europeans (P < 0·05) who more often consider potassium perchlorate as an useful addition (31%vs. 15% of North Americans, P < 0·01). Glucocorticoids are the selected treatment for type 2 AIT, alone (62%vs. 46% in Europe, P < 0·05) or in association with thionamides (16%vs. 25% in Europe, P = NS). After restoration of euthyroidism, thyroid ablation in the absence of recurrent thyrotoxicosis is recommended in type 1 AIT less frequently by North Americans. If amiodarone therapy needs to be reinstituted, prophylactic thyroid ablation is advised by 76% in type 1 AIT, while a ‘wait‐and‐see’ strategy is adopted by 61% in type 2 AIT, similar to behaviour of European thyroidologists. Conclusion Similarities and differences exist between expert North American and European thyroidologists concerning the diagnosis and management of AIT. While differences reflect the frequent uncertainty of the underlying mechanism leading to AIT, similarities may represent the basis to refine the diagnostic criteria and to improve the therapeutic outcomes of this challenging clinical situation. 相似文献
24.
Giordano R Picu A Broglio F Bonelli L Baldi M Berardelli R Ghigo E Arvat E 《Pituitary》2004,7(4):243-248
Ghrelin, a peptide predominantly produced by the stomach, has been discovered as a natural ligand of the GH Secretagogue receptor
type 1a (GHS-R1a), known as specific for synthetic GHS. Ghrelin has recently attracted considerable interest as a new orexigenic
factor. However, ghrelin exerts pleiotropic actions that are explained by the widespread distribution of ghrelin and GHS-R
expression. Besides strong stimulation of GH secretion, the neuroendocrine ghrelin actions also include significant stimulation
of both lactotroph and corticotroph secretion; all these actions depend on acylation of ghrelin in serine-3 that allows binding
and activation of the GHS-R1a. However, GHS-R subtypes are likely to exist; they also bind unacylated ghrelin that is, in
fact, the most abundant circulating form and exerts some biological actions. Ghrelin secretion is mainly regulated by metabolic
signals, namely inhibited by feeding, glucose and insulin while stimulated by energy restriction. The role of glucocorticoids
on ghrelin synthesis and secretion is still unclear although morning ghrelin levels have been found reduced in some patients
with Cushing's syndrome; this, however, would simply reflect its negative association to body mass. Ghrelin, like synthetic
GHS, stimulates ACTH and cortisol secretion in normal subjects and this effect is generally sensitive to the negative glucocorticoid
feedback. It is remarkable that, despite hypercortisolism, ghrelin as well as synthetic GHS display marked increase in their
stimulatory effect on ACTH and cortisol secretion in patients with Cushing's disease. This is even more intriguing considering
that the GH response to ghrelin and GHS is markedly reduced by glucocorticoid excess. It has been demonstrated that the ACTH-releasing
effect of ghrelin and GHS is purely mediated at the central level in physiological conditions; its enhancement in the presence
of ACTH-secreting tumours is, instead, likely to reflect direct action on GHS receptors present on the neoplastic tissues.
In fact, peculiar ACTH hyperresponsiveness to ghrelin and GHS has been observed also in ectopic ACTH-secreting tumours. 相似文献
25.
Morales A Morimoto S Díaz L Robles G Díaz-Sánchez V 《The Journal of endocrinology》2008,197(2):309-314
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an endothelial cell mitogen, expressed essentially in steroidogenic cells. Recently, the expression of EG-VEGF in normal human pancreas and pancreatic adenocarcinoma has been demonstrated. Epidemiologically, pancreatic carcinogenesis is more frequent in males than females, and given that androgen receptors and testosterone biotransformation have been described in pancreas, we hypothesized that testosterone could participate in the regulation of EG-VEGF expression. In this study, we investigated the regulation of EG-VEGF gene expression by testosterone in normal rat pancreatic tissue and rat insulinoma cells (RINm5F). Total RNA was extracted from rat pancreas and cultured cells. Gene expression was studied by real-time PCR and protein detection by immunohistochemistry. Serum testosterone was quantified by RIA. Results showed that EG-VEGF is expressed predominantly in pancreatic islets and vascular endothelium, as well as in RINm5F cells. EG-VEGF gene expression was lower in the pancreas of rats with higher testosterone serum levels. A similar effect that was reverted by flutamide was observed in testosterone-treated RINm5F cells. In summary, testosterone down-regulated EG-VEGF gene expression in rat pancreatic tissue and RINm5F cells. This effect could be mediated by the androgen receptor. To our knowledge, this is the first time that a direct effect of testosterone on EG-VEGF gene expression in rat pancreas and RINm5F cells is demonstrated. 相似文献
26.
27.
Lorenza Di Pascoli Alessra Buja Massimo Bolognesi Sara Montagnese Angelo Gatta Dario Gregori Carlo Merkel 《World journal of gastroenterology : WJG》2014,20(30):10464-10469
AIM:To evaluate the most cost-effectiveness strategy for preventing variceal growth and bleeding in patients with cirrhosis and small esophageal varices.METHODS:A stochastic analysis based on decision trees was performed to compare the cost-effectiveness of beta-blockers therapy starting from a diagnosis of small varices(Strategy 1)with that of endoscopic surveillance followed by beta-blockers treatment when large varices are demonstrated(Strategy 2),for preventing variceal growth,bleeding and death in patients with cirrhosis and small esophageal varices.The basic nodes of the tree were gastrointestinal endoscopy,inpatient admission and treatment for bleeding,as required.All estimates were performed using a Monte Carlo microsimulation technique,consisting in simulating observations from known probability distributions depicted in the model.Eight-hundred-thousand simulations were performed to obtain the final estimates.All estimates were then subjected to Monte Carlo Probabilistic sensitivity analysis,to assess the impact of the variability of such estimates on the outcome distributions.RESULTS:The event rate(considered as progression of varices or bleeding or death)in Strategy 1[24.09%(95%CI:14.89%-33.29%)]was significantly lower than in Strategy 2[60.00%(95%CI:48.91%-71.08%)].The mean cost(up to the first event)associated with Strategy 1[823£(95%CI:106£-2036£)]was not significantly different from that of Strategy 2[799£(95%CI:0£-3498£)].The cost-effectiveness ratio with respect to this endpoint was equal to 50.26£(95%CI:-504.37£-604.89£)per event avoided over the four-year follow-up.When bleeding episodes/deaths in subjects whose varices had grown were included,the mean cost associated with Strategy 1 was 1028£(95%CI:122£-2581£),while 1699£(95%CI:171£-4674£)in Strategy 2.CONCLUSION:Beta-blocker therapy turn out to be more effective and less expensive than endoscopic surveillance for primary prophylaxis of bleeding in patients with cirrhosis and small varices. 相似文献
28.
Roberta Sellaro Bernhard Hommel Lorenza S. Colzato 《Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale》2014,232(1):113-119
Recent studies suggest that recreational use of cocaine is associated with significant impairments in the same cognitive control functions that are affected by chronic use. Here we tested whether recreational cocaine use can impact the emergence and resolution of response conflict in conflict-inducing tasks. Recreational cocaine polydrug users (n = 17) and cocaine-free controls (n = 17), matched for sex, age, intelligence, and alcohol consumption, performed a Simon task—which is known to induce response conflict. Recreational users showed a larger Simon effect, indicating that they had more difficulty resolving stimulus-induced response conflict. This finding is consistent with the recent literature showing that even small doses of cocaine are sufficient to compromise key cognitive control functions. 相似文献
29.
30.
Sorafenib and lenvatinib are approved for first‐line treatment of patients with advanced hepatocellular carcinoma (HCC), and the efficacy of atezolizumab plus bevacizumab has been demonstrated versus sorafenib. Over time, first‐line treatment frequently fails, and regorafenib, cabozantinib, ramucirumab (for patients with alpha fetoprotein ≥400 ng/mL), nivolumab, pembrolizumab and ipilimumab plus nivolumab are approved for use after sorafenib (but not lenvatinib) treatment in advanced HCC. Given the considerable complexity in the therapeutic landscape, the objective of this review was to summarize the clinical evidence for second‐line agents and provide practical guidance for selecting the best sequential treatment approach. The timing and sequencing of treatment switches are key to optimizing patient outcomes in advanced HCC, and decisions should be informed by reasons for discontinuation of previous therapy and disease progression. It is important not to switch too soon, because sequential treatment benefit may then be lost, nor should switching be delayed too long. Effectiveness, safety and tolerability, patient quality of life, route of administration, dosing regimen, drug class, molecular target and individual patients’ characteristics, including comorbidities, inform the selection of second‐line systemic treatment, independently of the aetiology of HCC, tumour stage and the response to previous treatment. Biomarkers predictive of treatment effectiveness are of great value, but currently biomarker‐driven patient selection is possible only in the case of ramucirumab. The approval of new combination therapies for advanced HCC in the first‐line setting will further increase the complexity of decision‐making. However, the important factors will remain the individual patient’s characteristics and preferences. 相似文献